WO2017090902A1 - Oral hemostatic and wound-protective film - Google Patents

Abstract

The present invention relates to an oral hemostatic and wound-protective film which can be attached to a cut portion in an oral cavity so as to delay or prevent microbleeding and to control release of medicinal ingredients. The present invention comprises polyol, alcohol and a biodegradable polymer in a partly swollen state, thereby being capable of absorbing blood or abscesses in a topical region and stopping bleeding. Further, as the film of the present invention has a large elongation rate , it is possible to maintain an adhesive force after absorbing blood, saliva and abscesses in an oral cavity. In addition, as the film easily transforms to a topical site with curvatures, the film is less irritating even when attached to such a topical site for a long time. Further, as the film of the present invention comprises a disintegrating agent which is dissolved and released when reacting with blood to form microchannels serving as a drug release passage, it is possible to control a drug release amount by controlling the amount and size of the microchannels. Since an adhesive layer and a support layer of the present invention are dissolved and removed over time, a patient does not have to detach a transporter film attached in the oral cavity by hand .

Description

Oral hemostasis and wound protection film

The present invention relates to oral hemostasis and wound protection film, and more particularly, to oral hemostasis and wound protection film that can be attached to the wound site of the oral cavity to delay or prevent microbleeding and control the release of the active ingredient.

Drug delivery through the oral mucosa is very useful for drugs that are easily metabolized during oral administration, drugs with low bioavailability, and those with gastrointestinal disorders, which are easy to apply and remove, and are irritated or damaged compared to other mucosa. Because it is less sensitive to, it is attracting attention as a route of administration of new drugs. Therefore, not only simple oral disease treatment, but also various drugs capable of systemic delivery in a small amount can be applied to the oral mucosa.

The formulations applied to the oral mucosa mainly consist of liquids, troches, and ointments. However, these formulations do not have a constant single dose, and the applied drug is easily lost by saliva, and thus, a constant drug cannot be expected.

Korean Patent Laid-Open Publication No. 10-2005-0055898 discloses a technique of forming a protective film that prevents the penetration of saliva, such as saliva, on the surface of a drug formulation in a liquid or gel form to prevent the drug from being easily lost. However, even when such a protective film is formed on the surface of the gel, it is difficult to use for a long time, and there is a problem of preventing drug release depending on the type of polymer or the thickness of the layer.

Recently, oral mucoadhesive films have been developed to solve the problem of ointments or gel type preparations (eg RAPIDFILM, tesa Labtec GmbH). However, these adherent films can exhibit a constant dose and efficacy, while in a short time (about 3 minutes) the film melts and releases all of the active ingredients locally orally or temporarily in the digestive tract. There was a problem.

Korean Patent Laid-Open Publication No. 10-2005-0119914 discloses a tooth- and gum-attachable sheet that can be attached for a long time, but the sheet is composed of four layers, which maintains a relatively large thickness. There was a problem in that there was a sense of foreign body, which not only lowered the patient's compliance, but also easily detached from the oral mucosa by swelling by saliva. In addition, it includes a water-insoluble adhesive layer, so that the patient has to detach the sheet attached to the oral cavity by hand, and the inconvenience of use along with the cleaning problem has been raised. Although there are inventions for fast-release preparations that are rapidly releasing in domestic and foreign markets, there are no mucoadhesive preparations that adhere to the oral cavity and release controlled drug substances. Indeed, products such as Listerin's Breath Strip, sold in the United States, are in the form of a film that melts in about 3 minutes in the oral cavity.

The present invention is to provide oral hemostasis and wound protection film that can be attached to the oral mucosa, which can absorb or emulsify the blood or abscess.

The present invention provides an oral hemostasis and wound protection film that can control the release of the drug substance while being attached for a long time in the oral cavity for 10 minutes or more.

The present invention provides a thin film oral hemostasis and wound protection film that does not easily separate in the oral cavity without the patient feeling foreign body.

The present invention provides an oral hemostasis and wound protection film which does not require the patient to detach the sheet attached to the oral cavity by hand.

One aspect of the present invention

 An adhesive layer comprising any one or more of a surfactant, an oil and a plasticizer, a hydrophilic polymer, and a disintegrant, attached to a wound site to delay or prevent microbleeding; And

Comprising a water-insoluble polymer, comprising a support layer on the adhesive layer to protect the adhesive layer from the tongue, saliva or food in the oral cavity,

The disintegrant is related to oral hemostasis and wound protection film, characterized in that the dissolution is released upon reaction with blood to form microchannels in the adhesive layer.

The present invention may include polyols, alcohols, and biodegradable polymers in a partially swollen state to absorb and bleed local blood or abscesses. In addition, the film of the present invention has a high elongation rate and thus maintains adhesion even when absorbing blood, saliva and abscess in the oral cavity. . In addition, the film of the present invention may include a disintegrant which dissolves and reacts with blood to form microchannels that become drug release pathways, thereby controlling the amount and size of the drug release.

In the present invention, since both the adhesive layer and the support layer are lost and removed over time, the patient does not need to detach the carrier film attached to the oral cavity by hand.

1 is a conceptual diagram of the oral hemostasis and wound protection film of the present invention.

The present invention can all be achieved by the following description. The following description is to be understood as describing preferred embodiments of the invention, but the invention is not necessarily limited thereto.

1 is a conceptual diagram of the oral hemostasis and wound protection film of the present invention. Referring to FIG. 1, the film includes an adhesive layer 10 and a support layer 20.

The adhesive layer 10 is attached to one surface is in direct contact with oral hard tissue or soft tissue, the support layer 20 is formed on the other surface of the adhesive layer 10 so that the adhesive layer is not easily dissolved by tongue or saliva. do.

The adhesive layer 10 includes at least one of a surfactant, an oil and a plasticizer, and a hydrophilic polymer and a disintegrant. The adhesive layer may further include a drug.

The hydrophilic polymer functions as a base material of the adhesive layer, and the hydrophilic polymer uses a polymer that generates adhesion when hydrated. For example, the hydrophilic polymer is a cellulose-based polymer of carboxymethyl cellulose, carboxypropyl cellulose or a salt thereof, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl ethyl cellulose, gum The series of polymers are gelangum, xanthan gum, guar gum, carrageenan gum, Karayan gum, arabic gum and alginate gum. Or salt derivatives thereof, and gelatin, synthetic polymers such as polyvinyl alcohol, poloxamer, polyvinylpyrrolidone, polyvinylpyrrolidone-vinylacetate copolymer, polyacrylic acid, carbopol, polyquater Nium-11, 39 (polyquaternium-11, 39), polyalkylvinylether-maleic acid copolymer (PVM / MA copolymer: Gantgrez AN 119, 139, S-97), and polyox Gin may be used alone or in combination of two or more selected from the group.

The adhesive layer includes any one or more of a surfactant, an oil, and a plasticizer. The said surfactant can hold | maintain the said disintegrant and the lipophilic softener mentioned later in a stable state in a hydrophilic solvent.

The surfactant may be a variety of surfactants, including pharmaceutically acceptable anionic, cationic, nonionic or amphoteric surfactants. As an example, the surfactant may be a polyoxyethylene glycolated natural or hydrogenated castor oil, an ester of mono or trilauryl, palmityl, stearyl or oleyl, polyoxyethylene stearic acid ester, polyoxyethylene-polyoxypropylene Copolymer, polyoxyethylene-polyoxypropylene block copolymer, sodium dioctylsulfosuccinate or sodium lauryl sulfosate, phospholipids, propylene glycol dicaprylate, propylene glycol dilaurate, propylene glycol isostearate, propylene glycol laurate Latex, propylene glycol ricinoleate or propylene glycol caprylic-capric acid diesters, trans-esterification reaction products of natural vegetable oil triglycerides with polyalkylene polyols, capryl / capric acid mono- or di-glycerol Ride, sorbitan fatty acid esters, sorb Tan mono LA may be greater than or equal to us, at least one selected from sorbitan or sorbitan palmityl stearyl group consisting of cholesterol, phytosterol and sitosterol.

The oil may be silicone oil, liquid paraffin, rosin wax solution, soybean oil, olive oil, sesame oil, castor oil, fat soluble vitamins, fat soluble vitamin acetate, and the like. The oils can also serve as plasticizers.

The plasticizer used to impart flexibility and elasticity to the film may be selected from the group consisting of acetyl triethyl citrate, citrate ester, tricetin and triethyl citrate.

The disintegrant may be dissolved and released upon reaction with blood to form microchannels in the adhesive layer, and the drug may be released through the channel. By controlling the amount of disintegrant, the size and distribution of the channel can be controlled, thereby controlling the amount of drug released.

The disintegrant may be any one or more selected from polyols such as glycol, glycerin, sorbitol, and sebum, and xylitol lactose, magnesium stearate, crystalline cellulose, and crospovidone.

The drug includes all drugs suitable for absorption from the oral mucosa.

In addition, known oral treatments, periodontal acid coating material and the like may also be applicable. For example, drugs that can be used in the present invention include oral disease agents such as anti-inflammatory agents and fungicides, antihistamines, tissue repair agents, hemostatic agents, hormones, antihypertensive agents, antibiotics, and bronchodilators.

Examples of anti-inflammatory agents include trinexamic acid, lysozyme chloride, sodium azulene sulfonate, dipotassium glycyrrhinate, ammonium glycyrrhinate, glycyrrhetinic acid, bromeloline, serapeptase, pranopropene, ibuprofenpiconol, furesterone, and root root Extract, epidahydrocholesterin, bupecsa film, upenamat, mylar tincture, shiho, fukyeong, yellow white, hydrocortisone acetate, predonisolone acetate, predonisolone, hydrocrtisone, triamcinolone acetonide, and the like.

Examples of the disinfectant include potassium iodide, liquid phenol phenol, cetylpyridinium chloride, chlorohexidine gluconate, chlorhexidine hydrochloride, decualinium chloride, creosote, thymol, triclocarbam, benzalkonium chloride and benzyl chloride Tonium, acriol, oxydol, ethanol, isopropanol, mercurochrome, cresol, isopropylmethylphenol, phenyl salicylate, sulfadiazine, homosulfamine, cinnamon oil and the like.

Examples of the antihistamines include chlorpheniramine maleic acid, diphenhydramine salicylic acid, diphenylpyralline hydrochloride, mequitazine hydrochloride, triprolidine hydrochloride, maleic acid carbinoxamine, diphenhydramine hydrochloride, diphenhydramine tannin acid, dimenhydrinate and hydrochloric acid. Promethazine, the prooxamic acid promethazine, meclizin hydrochloride, isopentyl hydrochloride, and the like.

 Examples of tissue repair agents include sodium copper chlorophyllin, allantoin, aldioxa, methylmethioninesulfonium chloride, squavalate, asiaticoside, hydrochloric acid setlaxate, sofalcone, gefarnate, maleic acid tributhin, teflon and heparin-like. Substances, and the like.

Examples of local anesthetics include dibucaine hydrochloride, dibucaine, lidocaine hydrochloride, lidocaine, ethyl benzoate, oxetase, and ticaine.

Cinnamon oil, cinnamon oil, myrrh tincture, sea tiger, Fuling, yellowish white, sperm component, dense tincture, latania tincture, soft-hopping, horse riding, gilyeong, safflower and the like.

 Other components include topical protective agents such as glycerin and concentrated glycerin, topical stimulants such as l-menthol, peppermint oil and dl-menthol, tissue astringents and disinfectants such as hinoki thiol, hemostatic agents such as carbazochrome, ascorbic acid and susu Vitamins such as calcium corbate, calcium tocopherol acetate and tocopherol zucchini, pantothenol, pyridoxine hydrochloride, blood circulation promoters such as benzyl nicotinate, blood circulation promoters such as sodium polyethylenesulfate, and antibiotics such as minocycline hydrochloride.

The adhesive layer may include 0.1 to 60 parts by weight of the surfactant, oil or plasticizer and 0.1 to 30 parts by weight of the disintegrant, relative to 100 parts by weight of the hydrophilic polymer.

The adhesive layer may include 0.1 to 60 parts by weight of the surfactant or oil, preferably 1 to 40 parts by weight, and more preferably 1 to 30 parts by weight, based on 100 parts by weight of the hydrophilic polymer.

The adhesive layer may include 0.1 to 60 parts by weight, preferably 1 to 40 parts by weight, more preferably 1 to 20 parts by weight, and more preferably 1 to 15 parts by weight, based on 100 parts by weight of the hydrophilic polymer. have.

The disintegrant may be used 0.1 to 30 parts by weight, preferably 1 to 25 parts by weight, more preferably 1 to 20 parts by weight relative to 100 parts by weight of the hydrophilic polymer.

The adhesive layer may include 0.01 to 20 parts by weight of the drug relative to 100 parts by weight of the hydrophilic polymer.

The adhesive layer may be attached to the oral mucosa in a swollen state, including 0.1 to 30% by weight of water relative to the total weight of the adhesive layer. When the pressure-sensitive adhesive layer contains water in the above range, the swelling state is maintained for a long time, so that the absorption of blood or abscess can be performed more quickly. Here, partial swelling means that the pressure-sensitive adhesive layer is not fully swollen.

The adhesive layer may further include 0.1 to 30 parts by weight of a lipophilic softener relative to 100 parts by weight of the hydrophilic polymer.

The hydrophilic polymer and the drug forming the pressure-sensitive adhesive layer is dissolved by saliva and gradually lost. However, since the lipophilic softener is not dissolved by saliva, the relative content in the pressure-sensitive adhesive layer increases over time. The lipophilic softener with increased relative content in the adhesive layer gradually penetrates into the adjacent support layer to soften the support layer 20, and as a result, the support layer is lost by saliva.

That is, the softener of the present invention serves to soften and lose the support layer, which is a water-insoluble layer, by moving the material from the pressure-sensitive adhesive layer 10 to the support layer 20 over time. As a result, the drug delivery system of the present invention prevents the adhesive layer from rapidly decomposing due to the slow disappearance of the support layer, thereby enabling sustained release of the drug.

The drug release time and the content of the drug carrier (film) can be controlled according to the content of the softener and the thickness of the support layer.

The softener may be any one selected from triethyl citrate, dibutyl sebacate, acetyl triethyl citrate and triacetin.

The adhesive layer may be formed by dissolving the components in a solvent and then drying. The solvent may be water, methanol, ethanol, acetone, isopropanol, ethyl acetate and the like, preferably water is used.

The adhesive layer may have a thickness of 50 to 1,500 µm, preferably 100 to 1200 µm, and most preferably 600 to 1,200 µm.

The support layer 20 may be prepared by mixing a water-insoluble polymer in a solvent. The support layer is located on the adhesive layer serves to protect the adhesive layer from the tongue and food in the oral cavity. In addition, the support layer 20 of the present invention may be softened and lost by the softening agent of the adhesive layer as described above.

The support layer 20 may have a thickness of 5 to 300 μm, preferably 10 to 150 μm, and most preferably 10 to 80 μm.

The water-insoluble polymer is polyvinylacetate, ethyl cellulose, polymethyl methacrylate, methacrylic acid copolymers, for example methacryloylethylbetaine / methacrylate copolymer (yukaformer), methacrylic copolymer, amino Alkylmethacrylate copolymers (Eudragit E, RL), cellulose acetate phthalate, shellac, polyethylene, PVC, polyurethane, polyethylene alone or mixtures thereof.

The support layer may be used by dissolving a surfactant, a plasticizer, or an oil and a softener in a solvent.

Hereinafter, preferred embodiments are provided to help understanding of the present invention, but the following examples are provided only for easier understanding of the present invention, and the present invention is not limited thereto.

Examples 1-7, Comparative Examples 1-4

To prepare a pressure-sensitive adhesive layer solution and a support layer solution using the components shown in Table 1 and Table 2. First, a pressure-sensitive adhesive layer solution was applied on the release layer and then dried to prepare a pressure-sensitive adhesive layer film. Subsequently, the support layer solution was applied onto the adhesion layer film and dried. The bilayer film thus prepared was cut to a predetermined size.

Raw material classification	Details	Example							Comparative example
		One	2	3	4	5	6	7	One	4
Surfactants	Sorbitan monooleate	5	5	5	5	5	3	5
	Sorbitan fatty acid ester	5	4	5	4	4	4	4
	Polyoxyethylene-Polyoxypropylene Copolymer		One
	Sodium Lauryl Sulfoate				One	One	One	One
Plasticizer / oil	Silicone oil	One				One	One	One
	Liquid paraffin	4	5
	Castor oil			5	5	4	4	4
Softener	Triethyl citrate	5		5			5		5	5
	Dibutyl sebacate		5					5
	Acetyl triethyl citrate				5	One	One	One
Polymer	Hydroxyethyl cellulose	5		5	5	34	26	15
	Povidone	52	45			25		24
	Polyvinyl alcohol		5	50	60		20	15
	Xanthan Gum		2			5
	Carbopol 934P								4	4
	Hydroxypropyl cellulose								24	24
Disintegrant	Crospovidone	3	5	5			5	5
	Propylene glycol			2	2	2	One
	PEG-400		One		5			2
	glycerin					5
	Sorbitol					2
Medicinal substances	Vitamin E	One
	CPC			0.1
	Dexmethasone		0.1						0.1
	Dibucaine Hydrochloride
additive	Pigment Blue # 1 (1% Sol’n)	One	One	One					One
	Spices	One	One	One
	pH regulator	0.1
menstruum	water	16.9	19.9	15.9	5.9	9.9	30	10
	ethanol					One	One	One	TO 200	TO 200
	Acetone				2
Sum		100	100	100	99.9	99.9	96	86

Comparative Example 2 uses Reso-Pac®, and Comparative Example 3 uses dental hygiene gauze.

Raw material classification	Details	Example							Comparative example
		One	2	3	4	5	6	7	One	4
Surfactants	Sorbitan monooleate	2					2
	Sorbitan fatty acid ester		4	2	4	4	4
	Polyoxyethylene-Polyoxypropylene Copolymer		One		One	One	One
	Sodium Lauryl Sulfoate			One
Plasticizer / oil	glycerin	One	One		One	One	One
	Liquid paraffin	One	2		2	2	2
Softener	Triethyl citrate	5		5					18	18
	Dibutyl sebacate		5		5		5
	Acetyl triethyl citrate
Polymer	Polyvinylacetate			5
	Ethyl cellulose	50	65		65	65	65		18	18
	Methacryl copolymer		5	50	5	5	5
	Polyethylene							100
	Eudragit								18	18
menstruum	ethanol	TO 100	TO 100	TO 100	TO 100	TO 100	TO 100	TO 100	TO 100	TO 100
	Acetone		2	2
Sum			102	102

Experiment 1: Dissolution Rate Test

Oral hemostasis and wound protection films (hereinafter, hemostatic film) prepared in Examples 1 to 3 and Comparative Example 1 were used as dissolution rate test samples. According to the dissolution test method 2 (paddle method) of the Korean Pharmacopoeia general test method. Specifically, the eluate was eluted at 900 mL (pH 6.8 liquid), at a temperature of 37 ± 0.5 ° C., and at a rotational speed of 50 rpm. The eluate was taken at 10 minute intervals from the beginning of the experiment and evaluated from 5 minutes to 1 hour. As the eluting material, blue # 1 dye was used, and the degree of release was divided into five stages and visually evaluated. The results are shown in Table 3.

	Measuring time	Dissolution rate
		Example			Comparative example
		One	2	3	One
One	1 min	One	One	2	One
2	5 minutes	2	3	3	One
3	10 minutes	3	4	4	2
4	30 minutes	4	4	4	3

(4-point scale 1: almost transparent 2: light blue 3: blue 4: dark blue)

Table 3 shows that Examples 1 to 3 release the pigment at a faster time than Comparative Example 1. In addition, the pigment release time of Examples 2 and 3 containing more disintegrant was faster than that of Example 1. That is, Table 1 shows faster release with more disintegrants. The rate of release can be controlled by adjusting the disintegrant.

Experiment 2: Evaluation of Wound Healing

The degree of wound healing was evaluated with the oral hemostasis and wound protection films (hereinafter hemostatic film) prepared in Examples 4 to 6 and Comparative Examples 2 and 4. Seventy-two male Sprague-Dawley rats (16 to 18 weeks old) were divided into three groups and stored in a standard breeding case. 5% isoflurane, ketamine hydrochloride, and xylaizne were used and local anesthesia was performed with lidocaine. Surgical defects were used for 5 mm trephine bur. The experimental group and the control group were applied to the wounded area by calvarial defect procedure, and the wound healing was compared 4 and 8 weeks after the closure.

	Measuring time	Wound healing
		Example			Comparative example
		3	4	5	2	4
One	4 Weeks	3	2	3	One	One
2	8 Weeks	4	3	3	2	2

(4-point scale 1: Same as before 2: Slightly healing 3: Healing 4: Normal level)

Referring to Table 4, Example 3 was shown to be more effective by the action of the bactericidal component CPC compared to Example 4. Examples 4 and 5 were similar in effect, but Example 5 was slightly more effective due to the high disintegrant and water content. With this ingredient, you can protect your dried skin first.

Reso-Pac®, Comparative Example 2, is an ointment preparation. This formulation is less effective in protecting the wound because it disappears over time when applied to the wound. In Comparative Example 4, no surfactant was used. Because of this, it is difficult to protect the wound in close contact with the wounded areas where the bends and oily components remain, and the stimulation caused by the excessive use of alcohol may have produced a reverse synergistic effect.

Experiment 3: Evaluation of Hemostatic Prevention

Oral hemostasis and wound protection film (hereinafter hemostatic film) prepared in Examples 4 to 6 and Comparative Examples 1 to 3 to evaluate the degree of hemostatic prevention is shown in Table 5. Absorption rate (ASTM D570) was applied as an evaluation method. Make the hemostatic film 10 × 10 (mm) in size and trap it in the mesh. Fill the spray bottle with saline solution (0.9% normal saline solution) and spray it 10 times on the hemostatic film in the mesh. Then, it is placed on a nonwoven fabric to remove excess moisture. And it compresses and compresses for 1 minute with a weight of about 10g to remove the surface moisture. The weight of the sample was obtained by subtracting the weight of the mesh and the absorbency was measured by the following equation. It was evaluated whether the absorption of blood or abscess can be reacted more rapidly according to the content of purified water inside the adhesive layer.

A (absorption rate) = (Wa-Wo) / Wo * 100

A: Absorption rate Wo: Initial film weight before absorption Wa: Film weight after spraying

Absorption rate (%)
Example			Comparative example
4	5	6	One	2	3
173	165	145	117	101	125

(4-point scale 1: Same as before 2: Slightly healing 3: Healing 4: Normal level)

In Examples 4 to 6, the overall water absorption was higher than that in Comparative Examples 1 to 3. Reso-Pac® of Comparative Example 2 had the lowest absorption. The gauze of Comparative Example 3 absorbed a certain amount of water when sprayed, but was discharged again when pressed with a weight of 10 g, so that it can be considered that it is easily dropped when there is physical contact with the tongue in the oral cavity. Low moisture content was advantageous to prevent hemostatic components. The degree of swelling was different according to the water content in the adhesive layer, and the lower the water content was, the more quickly it was possible to absorb blood or abscess.

Experiment 4: Usability Evaluation

Oral hemostasis and wound protection film (hereinafter hemostatic film) prepared in Examples 5, 6 and Comparative Examples 2 to 4 evaluated the usability and are shown in Table 6. Usability was judged by satisfaction according to the degree of comfort when attached to the oral cavity. Evaluation was conducted for 30 people.

Satisfaction Average Score
Example		Comparative example
5	6	2	3	4
3.5	3.7	2.5	1.5	2.4

(4-point scale 1: uncomfortable 2: slightly uncomfortable 3: convenient 4: very convenient)

Examples 5 and 6 scored higher than Comparative Examples 2-4. In Example 6, which had a high score, it was determined to be due to the synergistic effect of the surfactant, the plasticizer, and the softener. However, surfactants and plasticizers / oils can be used to some extent without the softener. The function of the above components seems to provide a condition for the polymer surface of the preparation to bind well with the micro surface of the oral mucosa as the polymer of the preparation becomes flexible at the molecular level. On the other hand, Comparative Example 2 had a large amount of foreign body in the form of ointment, Comparative Example 3 was the lowest satisfaction because it is possible to absorb the fluid due to the characteristics of the gauze, but low hemostasis. In Comparative Example 4, only the softener was used alone, and the usability effect was not high.

All simple modifications and variations of the present invention fall within the scope of the present invention, and the specific scope of the present invention will be apparent from the appended claims.

The present invention can be used as a film that can absorb and bleed local blood or abscesses.

Claims (7)

1. An adhesive layer comprising any one or more of a surfactant, an oil and a plasticizer, a hydrophilic polymer, and a disintegrant, attached to a wound site to delay or prevent microbleeding; And

   Comprising a water-insoluble polymer, comprising a support layer on the adhesive layer to protect the adhesive layer from the tongue, saliva or food in the oral cavity,

   The disintegrant is dissolved and released upon reaction with blood to form a microchannel in the adhesive layer oral hemostasis and wound protection film.
2. According to claim 1, wherein the disintegrant is oral hemostasis and wound protection film, characterized in that any one or more selected from glycol, glycerin, sorbitol or sebum, lactose, magnesium stearate, crystalline cellulose and crospovidone.
3. According to claim 1, wherein the adhesive layer is 100 parts by weight of the hydrophilic polymer

   0.1 to 60 parts by weight of the surfactant, oil or plasticizer; And

   Oral hemostasis and wound protection film comprising 0.1 to 30 parts by weight of the disintegrant.
4. The oral hemostasis and wound protection film of claim 1, wherein the adhesive layer is attached to the oral mucosa in a partially swollen state including 0.1 to 30 wt% of water.
5. The method of claim 1, wherein the adhesive layer comprises 0.1 to 30 parts by weight of a lipophilic softener relative to 100 parts by weight of the hydrophilic polymer,

   Oral hemostasis and wound protection film, wherein the softener penetrates into the support layer to soften the support layer as the adhesive layer disappears in the oral cavity, and the softened support layer is slowly lost by saliva.
6. 6. The oral hemostasis and wound protection film according to claim 5, wherein the softener is any one selected from triethyl citrate, dibutyl sebacate, acetyl triethyl citrate, and triacetin.
7. According to claim 1, wherein the film comprises 0.01 to 20 parts by weight of the drug relative to 100 parts by weight of the hydrophilic polymer, the drug is an anti-inflammatory agent, oral disease agents, antihistamines, hormones, hypertension treatment, antibiotics or bronchodilators, characterized in that Oral hemostasis and wound protection film.

Images